Elting LS - Search Results

1

Controversies in new antibiotic therapy for ambulatory patients.

Sundararajan V, Rubenstein EB, Rolston KV, Elting LS. Sundararajan V, et al. Among authors: elting ls. Support Care Cancer. 1997 Sep;5(5):358-64. doi: 10.1007/s005200050092. Support Care Cancer. 1997. PMID: 9322346 Review.

2

Beta-lactam regimens for the febrile neutropenic patient.

Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, Kantarjian H, Plager C, Murphy WK, Holmes F, et al. Bodey GP, et al. Among authors: elting ls. Cancer. 1990 Jan 1;65(1):9-16. doi: 10.1002/1097-0142(19900101)65:1<9::aid-cncr2820650105>3.0.co;2-c. Cancer. 1990. PMID: 2403484 Clinical Trial.

3

Medical futility and appropriate medical care in patients whose death is thought to be imminent.

Escalante CP, Martin CG, Elting LS, Rubenstein EB. Escalante CP, et al. Among authors: elting ls. Support Care Cancer. 1997 Jul;5(4):274-80. doi: 10.1007/s005200050074. Support Care Cancer. 1997. PMID: 9257423 Review.

4

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.

Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Elting LS, et al. Clin Infect Dis. 1997 Aug;25(2):247-59. doi: 10.1086/514550. Clin Infect Dis. 1997. PMID: 9332520

5

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.

Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbey EE, Manzullo E, Bodey GP. Elting LS, et al. Cancer. 1998 Dec 15;83(12):2597-607. doi: 10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l. Cancer. 1998. PMID: 9874468

6

Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.

Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G. Elting LS, et al. J Clin Oncol. 2000 Nov 1;18(21):3699-706. doi: 10.1200/JCO.2000.18.21.3699. J Clin Oncol. 2000. PMID: 11054443

7

A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.

Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L. Rolston KV, et al. Arch Intern Med. 1992 Feb;152(2):283-91. Arch Intern Med. 1992. PMID: 1739355 Clinical Trial.

8

Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients.

Rolston KV, Manzullo E, Elting L, Frisbee-Hume S, Rodriguez S, Rubenstein EB. Rolston KV, et al. Support Care Cancer. 1998 Jan;6(1):57-62. doi: 10.1007/s005200050133. Support Care Cancer. 1998. PMID: 9458538 Clinical Trial.

9

The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors.

Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS. Elting LS, et al. Cancer. 2002 Jun 15;94(12):3252-62. doi: 10.1002/cncr.10603. Cancer. 2002. PMID: 12115358 Free article.

10

Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.

Cantor SB, Elting LS, Hudson DV Jr, Rubenstein EB. Cantor SB, et al. Among authors: elting ls. Cancer. 2003 Jun 15;97(12):3099-106. doi: 10.1002/cncr.11447. Cancer. 2003. PMID: 12784347 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

195 results

Search Page